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Theroleofexerciseasadiagnosticortherapeutictoolinpatientswithametabolicdisease(MD)orneuromusculardisorder(NMD)
is relatively underresearched. In this paper we describe the metabolic proﬁles during exercise in 13 children (9 boys, 4 girls, age
5–15 yrs) with a diagnosed MD or NMD. Graded cardiopulmonary exercise tests and/or a 90-min prolonged submaximal exercise
test were performed. During exercise, respiratory gas-exchange and heart rate were monitored; blood and urine samples were
collected for biochemical analysis at set time points. Several characteristics in our patient group were observed, which reﬂected
the diﬀerences in pathophysiology of the various disorders. Metabolic proﬁles during exercises CPET and PXT seem helpful in the
evaluation of patients with a MD or NMD.
1.Introduction
Metabolic diseases (MDs) and Neuromuscular disorders
(NMDs) comprise a large heterogeneous group of diseases,
that directly (via intrinsic muscle pathology or defective
metabolic pathways) or indirectly (via nerve pathology),
impair muscle function and result in exercise intolerance.
Although the value of exercise tests in patients with
MD/NMD has been acknowledged for several decades [1–3],
the role of exercise stress tests as a diagnostic or evaluative
tool in children and adults with MD/NMD is relatively
underresearched. Moreover, exercise stress tests are not
standard for most centers to be performed in clinical care
[4–7]. In this paper, we provide two standardized exercise
tests with preliminary metabolic proﬁles in children with a
diagnosed MD/NMD for this purpose.
Exercise stress tests in patients with a metabolic disorder
involved in ATP synthesis show a clear speciﬁc metabolic
proﬁle during exercise [4] .T h e s em e t a b o l i cp r o ﬁ l e sc a nb e
useful as a reference for identifying patients for a possible
MD or NMD.
Therefore, the aim of the current study was to describe
the metabolic proﬁles during exercise in children with a
diagnosed NMD or MD. This information might be helpful
for clinicians in the diagnosis and follow-up of patients with
these disorders.
2. Methods
2.1. Subjects. In this retrospective chart review, patients with
an established diagnosis involving general ATP synthesis or
a dystrophinopathy, who were referred for exercise stress
testing to the Departments of Metabolic Diseases and Child
DevelopmentandExerciseCenter,UniversityMedicalCenter
Utrecht, the Netherlands, were included.2 International Journal of Pediatrics
Table 1: Cardiopulmonary measurements of patients during the CPET.
Patient Diagnosis Determination
of diagnosis
Age
(years) Sex Weight
(kg)
BMI
(Z-score)
HRpeak
(beats/min) RERpeak
VO2peak
(L/min)
(Z-score)
VO2peak /kg
(mL/min/kg)
(Z-score)
1G S D - 1 a Mutation R570X en
delta F327 11.9 M 40 19.3
(0.88) 205 1.16 1.99
(−0.04)
49.7
(−0.42)
2 GSD-III
Debranching enzyme
deﬁciency in
leucocytes
11.9 F 39 19.6
(0.71) 182 0.92
∗ 1.45
(−1.5)
37.1
(−1.5)
3G S D - 7 Phosphofructokinase
deﬁciency in muscle 12.9 M 32 13.1
(−3.7) 184 1.0 1.78
(−3.55)
34.6
(−3.24)
4M C A D
MCAD deﬁciency in
leucocytes
homozygous
Lys329Glu mutation
5.4 F 28 19.4
(1.98) 134 0.92
∗ 0.55
(−3.5)
19.5
(−4.2)
5M C A D MCAD deﬁciency in
leucocytes 11.4 F 42 18.9
(0.59) NA NA NA NA
6S C A D
SCAD deﬁciency in
leucocytes and
ﬁbroblasts; mutation
7.0 M 25 14.6
(0.70) 173 1.05 1.00
(−0.86)
40.1
(−1.9)
7M A D D MADD deﬁciency in
ﬁbroblasts 10.2 M 33 16.1
(−0.23) 195 1.25 1.33
(−1.1)
40.4
(−1.8)
8M A D D MADD deﬁciency in
ﬁbroblasts 8.6 M 25 14.1
(−1.35) 180 1.21 1.29
(0.09)
51.5
(−0.26)
9
2-
Methylacetoacetyl-
CoA-thiolase
deﬁciency
2-Methylacetoacetyl-
CoA-thiolase
deﬁciency in
ﬁbroblasts
8.7 M 30 15.5
(−0.32) 179 1.20 1.30
(−0.69)
43.5
(−1.4)
10
Mitochondrial
respiratory chain
myopathy
Diminished ATP
production in fresh
muscle biopsy
9.7 M 34 16.9
(0.30) 152 1.39 0.63
(−3.6)
18.5
(−5.0)
11 M. Becker
dystrophinopathy
Duplication exon
24-29 dystrophin
gene
10.4 M 25 12.4
(−3.6) NA NA NA NA
12 M. Becker
dystrophinopathy
Duplication exon
24-29 dystrophin
gene
14.8 M 57 18.6
(−0.22) 202 1.26 1.57
(1.7)
62.6
(2.7)
13 Hypokalemic
episodic paralysis
Arg1239His mutation
in CACNA1S-gene 13.8 F 62 24.5
(1.63) 218 1.25 1.20
(−2.0)
19.4
(−4.0)
Abbreviations:B M I :B o d yM a s sI n d e x ,H R peak: peak heart rate, VO2peak:p e a kO 2 uptake, RERpeak: peak respiratory exchange ratio, ∗: signiﬁcantly diﬀerent
from normal, NA: not assessed.
Thirteen patients (9 ♂,4♀, age 5–15 years) with
an established diagnoses were studied in detail. Diagnoses
were Glycogen Storage Disease (GSD) type 1a (1x), GSD
type 3 (1x), GSD type 7 (1x), Medium-Chain Acyl CoA
dehydrogenase deﬁciency (MCAD (2x)), Short-Chain Acyl
CoA dehydrogenase deﬁciency (SCAD (1x)), Multiple Acyl
CoA dehydrogenase deﬁciency (MADD (2x)), ketothiolase
deﬁciency (1x), mitochondrial myopathy (1x), Hypokalemic
episodic paralysis (1x), and dystrophinopathy (Becker Mus-
cular Dystrophy (BMD) (2x).
2.2. Exercise Tests. Two exercise stress tests, respectively,
a cardiopulmonary exercise test (CPET) and a prolonged
exercise ergometry test (PXT) were performed following
a standardized protocol [8]. Blood samples were taken,
immediatelybeforeanddirectlyaftertheCPETandPXT,and
analyzed for lactate, creatine kinase (CK), ammonia, acylcar-
nitines, and organic acid. Urine samples were collected up
to three hours after the exercise test and further analyzed
forcreatinine,organicacid,aminoacid,tetraglucose,purine,
and pyrimidine [8].
A CPET (to determine the peak oxygen uptake [VO2peak]
a n dp e a kw o r k l o a d[ W peak]) and a submaximal PXT
(90 minutes at 30% of Wpeak) were performed in the
morning. After a light breakfast, the patients performed a
symptom-limited CPET on a bicycle ergometer. Workload
was increased in constant increments of 10, 15, or 20
watts every minute, depending on the patients’ length
[9] and was in some conditions adjusted for the physical
condition of the patient. This protocol was continuedInternational Journal of Pediatrics 3
Table 2: Biochemical measurements of patients before and after the CPET.
Patient
Lactate CK Ammonia
(mmol/L) (U/L) (mmol/L)
Before After Before After Before After
13 . 5 ∗ 10.3 NA NA 5 4∗
2 2.2 1.6 540∗ 597∗ NA NA
3 0.8 2.4 246∗ 273∗ 61∗ 337∗
7 1.3 7.3 125 146 NA NA
81 . 3 6 . 0 7 9 8 9 N A N A
9 1.5 4.3 116 121 17 12
10 3.1∗ 6.9 85 100 8 6∗
12 1.5 13∗ 577∗ 773∗ 34∗ 54
Normal values
Mean (range)
1.56
(0.7–2.3)
7.0
(3.2–11.4)
104
(45–192)
123
(51–234)
18
(9–23)
42
(10–94)
Legend: NA: not assessed, ∗: signiﬁcantly diﬀerent from normal.
until the patient stopped due to volitional exhaustion,
despite strong verbal encouragement. During the tests, all
subjects breathed through a facemask (Hans Rudolph Inc.,
Kansas City, MO), connected to a calibrated respiratory
gas analysis system (Oxygen Champion/Pro, Care Fusion,
Houten, The Netherlands). This system measured breath-
by-breath minute ventilation (VE), oxygen uptake (VO2),
and respiratory exchange ratio (RER = VCO2/VO2) using
conventional equations. During the maximal exercise test,
heart rate (HR) was measured continuously by a bipolar
electrocardiogram. Peak HR (HRpeak),VO2peak,V O 2peak/kg,
and peak RER were taken as the average values over the last
30 seconds of the test.
A PXT was performed one week after the maximal
exercise test to prevent interference from the previous test.
The PXT consisted of a 90-minute cycling at a constant work
rate of 30% Wpeak, as described previously [8].
2.3. Blood and Urine Sampling and Analysis. Blood samples
were obtained from an indwelling catheter inserted into a
vein of the dorsum of the hand. Five milliliters of blood
from each sample was placed in lithium-heparin tube,
except for determination of FFA and ammonia; respectively,
normal blood (without Li-heparin) and EDTA (another
anticoagulant) blood was used for the analysis [8]. After
taking the blood, the tubes were stored in ice and brought
to the laboratory.
Blood taken before and after the CPET was analyzed for
lactate, creatine kinase (CK), ammonia, acylcarnitines, and
organic acid. Urine samples taken before and after the CPET,
were analyzed for creatinine, organic acid, amino acid, and
tetraglucose, until three hours after the exercise test.
During the PXT, blood samples were taken at regular
time intervals (t = 0, 30, 60, 75, 90, 105, and 120 minutes
after the start of the exercise). Concentrations of glucose,
lactate, CK, free fatty acids (FFA), ammonia, 3-OH-butyric
acidand3-keto-butyricacid,acylcarnitines,andorganicacid
were determined. Before and up to three hours after exercise,
urine samples were obtained and analyzed for creatinine,
organic acid, amino acid, and tetraglucose.
Glucose, lactate, CK, and ammonia were determined
with a Beckman Coulter DxC chemical analysis machine
(Fullerton, USA). Enzymatic method was used for determi-
nation of FFA, 3-ketobutyric acid, and 3-OH-butyric acid.
After lipoprotein lipase hydrolyzed triglyceride into fat acids
and glycerol, free glycerol was measured colorimetrically.
Organic acid concentration in urine and plasma was
determined by gas chromatography-mass spectrometry as
their trimethylsilyl derivates (Hewlett Packard 5890 series
II gas chromatograph linked to a HP 5989B MS-Engine
mass spectrometer (Hewlett Packard, Avondale, PA)). The
coeﬃcients of variation for the various measured organic
acids varied between 10%–15%. Analysis of acylcarnitine
in plasma as their butyl esters was performed by electro-
spray tandem mass spectrometry (ESI-MS-MS; Micromass
Quattro Ultima, Micromass Ltd., UK) equipped with an
Alliance HPLC system (Waters, Milford, MA, USA). Also for
these analyses the coeﬃcients of variation for the determined
acylcarnitines were 10%–15%. Analysis of amino acids in
plasma and urine was done with amino acid analyzer (ion-
exchange chromatography-ninhydrin).
3. Results
3.1. CPET. As expected, patients with a MD/NMD showed
abnormal results on the CPET (Tables 1 and 2). Patient 2
(GSD-3) stopped the CPET because of myalgia in the lower
limbs, compared to reference values for healthy children
[10, 11], the patients with GSD-3, MCAD, SCAD, and
mitochondrial myopathy (patients 4, 6, and 10, resp.) had
a signiﬁcantly reduced HRpeak. RERpeak was signiﬁcantly
lower in the patient with GSD-3 (patient 2) and also
in the patient with MCAD (patient 4) and surprisingly
increased to 1.0 in the patient with GSD-7 (patient 3).
VO2peak and VO2peak/kg were signiﬁcantly lower in the
patients 3, 4, 10, and 13. These were patients with GSD-7,4 International Journal of Pediatrics
Table 3: Biochemical measurements of patients during the PXT test.
Subject Time
(min)
Glucose
(mmol/L)
Lactate
(mmol/L)
FFA
(mmol/L)
3-Keto-B
(mmol/L)
3-OH-B
(mmol/L) CK (U/L) Ammonia
(µmol/L)
1
04 . 9 4 .3
∗ 0.51 0.14 0.0 116
30 4.4 4.6
∗ 0.52 0.13 0.02 115
60 5.7
∗ 2.8
∗ 0.489 0.12 0.02 119
75 5.6 3.1
∗ 0.536 0.12 0.02 119
90 6.7
∗ 2.9
∗ 0.559 0.12 0.02 121
15 after 7.4
∗ 4.1
∗ 0.792 0.13 0.04 121
30 after 7.5
∗ 4.9
∗ 0.666 0.12 0.04 118
3
0 5.5 1.8 0.08 0.0 0.0 166 22
30 5.9 1.2 0.14 0.0 0.0 181
∗
60 5.8
∗ 0.8 0.23 0.0 0.0 186
∗
75 6.9
∗ 1.2 0.36 0.09 0.04 187 275
∗
15 after 6.9 2.3 0.25 0.0 0.03 183
∗
30 after 2.0 0.26 0.0 0.0 184
∗ 144
∗
6
04 . 6 3 . 2 ∗ 0.268 0.12 0.0 48
30 4.6 1.3 0.302 0.1 0.0 46
60 4.4 1.4 0.444 0.12 0.0 48
15 after 4.6 1.1 0.503 0.13 0.03
30 after 4.7 0.9 0.528 0.13 0.03 51
7
0 7.1 1.1 0.76 0.07 0.09 103
30 5.6 1.2 0.28 0.0 0.0
60 4.9 1.0 0.49 0.0 0.0 98
75 4.8 1.3 0.88 0.05 0.05 105
90 5.5 1.1 1.03 0.10 0.12 119
30 after 4.8 1.0 0.93 0.15 0.26 117
8
0 5.2 2.0 0.15 0.0 0.0 58
30 4.6 0.9 0.31 0.0 0.0
60 4.3 0.9 0.62 0.07 0.04 80
75 4.4 1.0 0.91 78
30 after 4.5 1.2 1.34 0.14 0.24 78
9
0 6.4 1.4 0.22 0.09 0.03 90 14
30 4.9 1.4 0.18 0.0 0.0 93
60 4.7 1.3 0.21 0.0 0.0 89
75 4.4 1.1 0.42 0.0 0.0 99 22
90 4.9 1.1 0.64 0.11 0.11 91
15 after 4.8 0.8 0.69 0.13 0.18 92
30 after 4.6 1.0 0.55 0.14 0.2 92 14
10
04 . 0 2 .4
∗ 0.20 0.11 0.10
∗ 138 20
30 3.7
∗ 8.6
∗ 0.21 0.11 0.11
∗ 156
60 3.5
∗ 9.6
∗ 0.31 0.14 0.13 151
75 3.6
∗ 9.5
∗ 0.49 0.16 0.16 156 20
90 3.6
∗ 9.7
∗ 0.71 0.16 0.18 157
15 after 4.1 7.0
∗ 0.72 0.113 0.29 145
30 after 4.0 4.7
∗ 0.73 0.18 0.29 146
11
0 5.9 1.4 0.41 0.0 0.0 5020
∗ 7.0
30 4.8 1.4 0.19 0.0 0.0 4975
∗
15 after 5.3 1.4 0.57 0.0 0.0 5036
∗
30 after 5.2 1.3 0.5 0.0 0.0 18International Journal of Pediatrics 5
Table 3: Continued.
Subject Time
(min)
Glucose
(mmol/L)
Lactate
(mmol/L)
FFA
(mmol/L)
3-Keto-B
(mmol/L)
3-OH-B
(mmol/L) CK (U/L) Ammonia
(µmol/L)
12
0 5.1 1.1 0.15 0.0 0.0 695
∗ 33
∗
30 5.3 1.2 0.08 0.0 0.0 776
∗
60 5 1.2 0.11 0.0 0.0 774
∗
75 5.1 1.4 0.16
∗ 0.0 0.0 771
∗ 51
∗
90 5.0 1.7 0.23 0.0 0.0 766∗
15 after 5.1 1.1 0.76 0.0 0.0 755∗
Legend: FFA: free fatty acids, 3-keto-B: 3-ketobutaric acid, 3-OH-B: 3-hydroxybutaric acid, ∗: signiﬁcantly diﬀerent from normal.
MCAD,mitochondrialmyopathy,andHypokalemicepisodic
paralysis, respectively.
A remarkablyhigh VO2peak/kg wasobserved in one of the
patients with BMD (patient 12).
The patients with GSD-1a and mitochondrial myopathy
(patient 1 and 10, resp.) had signiﬁcantly increased lactate
concentrations at rest. Patient 2, with GSD-3, had an
increased CK values at rest and after exercise. The 2 patients
with BMD (patients 11 and 12) showed persistently highly
elevated CK levels. One patient (patient 13) showed mildly
elevated CK.
3.2. PXT. Biochemical proﬁles of the MD/NMD patients
during the PXT varied with the disorder (Table 3). Two
patients, one with GSD-1a and the other with mitochondrial
myopathy (resp., patient 1 and 10), showed signiﬁcantly
increased concentrations of blood lactate at all time points.
The patient, with GSD-7 had signiﬁcantly increased ammo-
nia concentrations with no rise in lactate during exercise.
During and after exercise, the CK value of the patient
with GSD-7 (patient 3) was signiﬁcantly increased as well as
in the 2 patients with BMD (patients 11 and 12).
Acylcarnitines C6, C8, C10, C12, and C14:1 were all
increased in two patients with MADD (patients 7 and 8) in
rest as well as during exercise. The patient with ketothiolase
deﬁciency (patient 9) had increased C5:1 and C5-OH acyl-
carnitine during rest and exercise, as well as several increased
organic acids in the urine. In the patient with mitochondrial
myopathy (patient 10), C5 carnitine was increased in the
urine during and after exercise. In the patient with SCAD
(patient 6), there was no C4 carnitine found. In all other
MD/NMD patients, no altered acylcarnitines, carnitines, for
organic acids concentrations could be observed in plasma or
urine (data not shown).
4. Discussion
The purpose of this study was to describe metabolic proﬁles
during exercise using CPET and PXT including extensive
blood and urine analyses in children with a diagnosed
MD/NMD. This information might be helpful for clinicians
in the diagnosis and follow-up of these disorders. Because
of the heterogeneity of the disorders, there was a large
variation in the CPET and PXT results between patients.
These diﬀerences reﬂect the diﬀerent pathophysiology of
the various disorders (e.g., defects in diﬀerent metabolic
pathways) and heterogeneity within disorders.
Metabolic proﬁling might be helpful in the further
workup towards a diagnosis. For example, a low rise in
lactate after CPET is suggestive for a GSD, and a very high
increase in lactate, combined with a very low VO2peak,m i g h t
be suggestive for a mitochondrial myopathy. Further studies
shoulddevelopanalgorithmfortheinterpretationofexercise
data in MD/NMD patients, comparable to the interpretative
algorithms for cardiac and pulmonary limitations during
exercise [12, 13].
The diagnostic yield of exercise stress testing in children
with unexplained exercise intolerance seems relatively low.
Among 29 patients referred for exercise intolerance of
unknown origin, only 3 patients could be diagnosed with
a MD/NMD: 2 patients with a Becker Muscular Dys-
trophinopathy and one patient with a hypokalemic episodic
paralysis. However, many of these patients have undergone
extensive medical screening before they were referred for
exercise testing. Ten percent is therefore a reasonable yield. It
is our opinion that the expense of exercise testing including
extensive blood and urine analyses is justiﬁed because it
could be useful for guiding the diagnostic workup and can
diﬀerentiate between patients with medically unexplained
exercise intolerance and patients with a MD/NMD. In
patients with a MD involved in ATP synthesis, only during
certain periods of metabolic stress (e.g., exercise, fasting,
or illness), abnormal quantities of metabolites in blood
and urine can be found, and symptoms are present. These
defects can only be indentiﬁed using standardized tests. The
current paper provides two standardized exercise tests with
preliminary metabolic proﬁles for this purpose.
Furthermore, several of the tested MD/NMD patients
(patients 3, 7, 8, and 10) were referred for exercise testing to
assess their exercise capacity for physical activity recommen-
dations. Based on their exercise results, an advice regarding
appropriatelevelsofphysicalactivitywasprovided.Suﬃcient
amounts of physical activity are necessary for an optimal
physical, psychosocial, and emotional development in chil-
dren [14].
In addition, for patient 12, we gave an exercise restriction
based on the ﬁndings. This patient was a talented cyclist with
av e ryh i ghV O 2peak for his age. However, during several races
he developed myoglobinuria, and he had quite high resting
values of CK. A muscle biopsy in the workup after the tests6 International Journal of Pediatrics
revealed a duplication in exon 24-29 of the dystrophin gene,
and the diagnosis of BMD was made. Based on these results,
the boy was advised to stop high-level cycling because of the
increased risk of renal failure due to myoglobinuria.
One of the limitations of this clinical report is the small
and heterogeneous population. This reﬂects the rarity of
the disorders. Therefore, multicentred studies are needed
to increase the sample size for each of the disorders.
Further, it is important that these proﬁles are established
in children as not all metabolic proﬁles seen in adults
are valid in children. For example, a recent study showed
that the well-known second-wind phenomenon in patients
with McArdle’s disease (GSD5), which is considered as a
diagnostic feature of this disease [15], was not observed in
children with McArdle’s disease [16].
5. Conclusion
In this paper we describe the metabolic proﬁles during exer-
cise in 13 children with a diagnosed MD/NMD. Metabolic
proﬁles during exercise were of assistance in diagnosing 3
patients with rare presentations of MD/NMDs. In addition,
exercise stress testing was helpful for the prescription of
a p p r o p r i a t el e v e l so fp h y s i c a la c t i v i t y .
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